NICE TO EVALUATE ENDOCUFF VISION®, A MEDICAL DEVICE TO HELP DETECT PRE-CANCEROUS POLYPS IN PATIENTS UNDERGOING BOWEL CANCER SCREENING
LONDON, UK, Friday 27 January 2017, 07:00 GMT. Norgine B.V. today announced that the National Institute for Health and Care Excellence (NICE) is evaluating
ENDOCUFF VISION® through its Medical Technologies Evaluation Programme. The evaluation will provide guidance on the use of the device in colonoscopy in patients undergoing bowel cancer screening and surveillance. 
Norgine anticipates receiving final guidance in October 2017.
ENDOCUFF VISION® is a Class I sterile medical device designed to attach to the end of the colonoscope that opens up the field of view by holding back colonic folds during colonoscope withdrawal. It is proven to significantly increase the detection of adenomas and polyps compared to standard colonoscopy.
Bowel cancer is the second most common cause of cancer-related mortality in the world , with nearly 1.4 million new cases diagnosed worldwide and 412,000 people in Europe. ,  The detection and removal of pre-cancerous polyps during colonoscopy substantially reduces both the development of and death from colorectal cancer.
Bob Cuffe, General Manager UK & ROI, Norgine, commented “Norgine is confident that the use of ENDOCUFF VISION® brings value to healthcare systems and patients by increasing the detection of cancerous polyps in patients undergoing bowel cancer screening and surveillance.”
ENDOCUFF VISION® is part of Norgine’s colonoscopy portfolio which includes KLEAN-PREP® and MOVIPREP®.
ENDOCUFF VISION® is available through Norgine’s infrastructure in: Australia, Austria, Belgium, Finland, France, Denmark, Germany, Italy, Ireland, Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland and the UK.
In the US and Canada it is available through Olympus Corporation of the Americas.
To see how it works click here
Notes to Editors:
Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2015, Norgine’s total revenue was EUR 320 million and the company employs over 1,000 people.
Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.
Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.
For more information, please visit www.norgine.com
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
NORGINE and the sail logo are trademarks of the Norgine group of companies.
Isabelle Jouin, T: +44 (0)1895 453643
Charlotte Andrews, T: +44 (0)1895 453607
Follow us @norgine
 Tsiamoulos et al. Gastrointestinal Endoscopy 2015;81(55) AB209. Abstract Sa 1423
 Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403
 Colorectal Cancer Statistics, World Cancer Research Fund International, http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/colorectal-cancer-statistics [Accessed 9 May 2015]
 Zavoral M et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009;15(47):5907-5915
 LeClercq CMC, Bouwens MWE, Rondagh, EJA et al. Postcolonoscopy colorectal cancers are preventable: a population-based study. Gut 2014;63:957-963